Not Enough High-Risk Women Being Screened for BRCA1/2

Share this content:
Not Enough High-Risk Women Being Screened for <i>BRCA1/2</i>
Not Enough High-Risk Women Being Screened for BRCA1/2

WEDNESDAY, Feb. 8, 2017 (HealthDay News) -- Many high-risk women don't get genetic testing for BRCA1 and BRCA2, often because they aren't advised to by their doctors, according to a research letter published in the Feb. 7 issue of the Journal of the American Medical Association.

A total of 2,529 women with breast cancer were questioned two months after surgery. The patients were asked if they had wanted genetic testing and, if so, whether they had received it. The women ranged in risk, with 31 percent having a high risk of carrying the BRCA mutations.

Among women with the highest risk, 80.9 percent said they wanted testing for the BRCA1 and BRCA2 mutations. But, "only about half of them actually got the testing they should get," study author Allison Kurian, M.D., an associate professor of medicine and of health research and policy from Stanford University's School of Medicine in California, told HealthDay. Of the high-risk women who were not tested, 56.1 percent said their doctors did not recommend it, the authors found. Asian-Americans and older women were particularly likely to not have been tested.

Furthermore, 39.6 percent of all high-risk women, and 61.7 percent of high-risk women who were tested, said they received genetic counseling, Kurian's team found. "I think it's very concerning," Kurian said of the findings. However, she noted that the survey was limited because it was based only on women's responses and recollections. For instance, doctors might have mentioned genetic testing and women might have forgotten that.

Kurian disclosed financial ties to Myriad Genetics, Invitae, and Ambry Genetics.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »